Contact Us Contact Us Contact Us

Updated July 2026

Pharma Guide · Buyer Checklist

6 Things to Check Before Choosing an Antibiotic Manufacturer in India

India accounts for approximately 20% of global antibiotic generic formulation exports by volume (Pharmexcil, 2024). But antibiotic manufacturing carries a facility requirement most buyers don’t know to ask about — dedicated, physically separated production for penicillin-class molecules. Six specific checks, including this one, separate genuine antibiotic manufacturing capability from a claim.

  • 10 companies reviewed
  • WHO-GMP verified criteria
  • 14 min read

  • WHO-GMP Status

    Active cert — not expired

  • Sample COA

    real batch data, 24 hours

  • DCGI Approvals

    molecule-level approval

  • COPP on file

    for your target country

  • Grade A/B cleanroom

    sterile injectable

  • Written by

    Bhavya Bhambani

    Content Writer, 9M India

  • Reviewed by

    Manish Agrawal

    MD, 9M India Limited

  • Fact-checked by

    Manish Shah

    Plant Head, 9M India

About 9M India Limited — examples and standards referenced in this guide

9M India Limited is a WHO-GMP certified pharmaceutical manufacturer established in 2009, located in Birkoni, District Mahasamund, Chhattisgarh. The company holds DCGI-approved manufacturing licences for antibiotics across injectable, tablet, capsule, and dry syrup dosage forms, spanning 200+ molecules. This guide uses 9M India’s documentation standards as the benchmark — COPP, FSC, COA, and stability data available within 24 hours, exports to 15+ countries.

Why these 6 checks matter — industry context

India is a primary global supplier of beta-lactam antibiotics, fluoroquinolones, macrolides, and aminoglycosides across tablet, capsule, injectable, and dry syrup forms to Africa, Middle East, South Asia, and South-East Asia. A verification challenge specific to antibiotics: WHO-GMP requires fully dedicated, physically separated manufacturing facilities for penicillin-class molecules specifically — a requirement that doesn’t apply to most other pharmaceutical categories, and one many buyers don’t know to ask about. These six checks are the practical buyer’s verification framework, drawn from the documentation requirements of NAFDAC (Nigeria), KEBS/PPB (Kenya), TFDA (Tanzania), and WHO prequalification guidelines.

Facility Requirement

Confirm WHO-GMP certificate covers your specific antibiotic class — beta-lactams need a dedicated facility

For penicillin-class antibiotics specifically, ask directly: does the manufacturer have a physically separated dedicated facility?

#1 of 6

For penicillin-class antibiotics, WHO-GMP requires completely dedicated, physically separated manufacturing facilities — a distinct building or validated enclosed unit — to prevent cross-contamination risk that can cause severe allergic reactions in sensitive patients. A shared facility cannot legitimately produce penicillin-class antibiotics under WHO-GMP.

How this requirement differs by antibiotic class
Cephalosporins (non-penicillin beta-lactams) require validated segregation and air-handling controls if manufactured in multi-product facilities, a lower bar than full physical separation. Non-beta-lactam antibiotics (fluoroquinolones, macrolides, aminoglycosides) can be manufactured in validated multi-product facilities with appropriate cleaning validation between batches.

How to verify - step by step

  • Ask directly: “Do you have a dedicated penicillin manufacturing facility?” Physically separated from all other products — not just a separate production line in the same building.

  • Request facility segregation documentation: For cephalosporins, ask for the validated segregation and air-handling control records.

  • Confirm this matches your specific molecule’s class: Penicillin, cephalosporin, and other classes carry different requirements.

  • Cross-check WHO-GMP certificate scope: The certificate should explicitly reference the antibiotic class and facility arrangement.

Antibiotic Class Facility Requirement
Penicillins Fully dedicated, physically separated facility
Cephalosporins Validated segregation + air-handling controls
Fluoroquinolones/Macrolides/Aminoglycosides Multi-product facility with validated cleaning

Why this check matters for export

Import regulators specifically verify facility segregation for penicillin-class antibiotic registrations — a manufacturer without dedicated facilities cannot legitimately supply this category regardless of other credentials. (WHO TRS No. 986, Annex 2)

Red flags to watch for

Manufacturer claims penicillin capability without confirming physical facility separation · No segregation documentation available for cephalosporin production · WHO-GMP certificate doesn’t specify antibiotic class scope · Vague answers about facility arrangement for beta-lactam production

From Industry Rankings

See how the top 10 antibiotic manufacturers in India compare on facility segregation

Our editorial ranking compares the top 10 antibiotic manufacturers in India across all 6 criteria in this guide — WHO-GMP facility scope, DCGI approvals, cross-dosage-form capability, COA rigor, export track record, and documentation speed.

See the full ranking

DCGI Approval

Confirm DCGI approval at the molecule AND dosage-form level

A manufacturer approved for Amoxicillin capsules is not automatically approved for Amoxicillin dry syrup or injection.

#2 of 6

Antibiotic DCGI approvals are molecule and dosage-form specific. A manufacturer may hold approval for one dosage form of an antibiotic but not another — each requires its own DCGI manufacturing licence.

Why this matters more for antibiotics — the widest cross-dosage-form category
Antibiotics span more dosage forms in practice than most therapeutic categories — oral tablets, capsules, dry syrups, and injectables all commonly exist for the same molecule. Confirm the manufacturer’s DCGI approval matches your exact molecule, strength, and dosage form — not just the molecule name.

How to verify — step by step

  • Request the DCGI licence for your exact dosage form: Tablet, capsule, dry syrup, or injectable — specifically.

  • Check the molecule and strength match exactly: Not just the same antibiotic family.

  • Verify facility segregation aligns with the antibiotic class: See Check 1 for penicillin-specific requirements.

  • Confirm approval is currently active: Not expired or under renewal.

Why this check matters for export
Import regulators require the dossier to cite a dosage-form-specific manufacturing licence for the antibiotic being registered — a mismatch is a common cause of query.

Red flags to watch for

Manufacturer presents approval for a different dosage form than requested · DCGI licence doesn’t specify exact strength · No clarity on facility segregation for the specific antibiotic class · Approval status unclear or pending renewal

Cross-Dosage Capability

Confirm cross-dosage-form capability if your programme needs multiple formats

Sourcing injectable and oral forms of the same antibiotic from one manufacturer simplifies your entire registration process.

#3 of 6

If your programme needs the same antibiotic in multiple formats — for example, injectable Ampicillin and Amoxicillin dry syrup — a manufacturer offering both under one WHO-GMP certification significantly simplifies documentation compared to sourcing from separate suppliers.

Why single-source cross-dosage capability matters practically
Each additional manufacturer in your supply chain means an additional COPP application, an additional set of stability data to track, and an additional relationship to manage for documentation turnaround. Consolidating under one manufacturer — where genuinely capable across your required dosage forms — reduces this operational overhead materially.

How to verify — step by step

  • List your full dosage-form requirement upfront: Injectable, tablet, capsule, syrup — whichever combination your programme needs.

  • Confirm DCGI approval exists for each dosage form separately: Cross-dosage capability requires separate approval per form, per Check 2.

  • Ask whether documentation can be consolidated: One COPP application process across dosage forms, where the manufacturer supports it.

  • Verify facility segregation still applies correctly across forms: Beta-lactam requirements apply regardless of dosage form.

Why this check matters for export

Fewer manufacturer relationships means fewer COPP applications and fewer points of documentation failure across your full antibiotic programme’s registration process.

Red flags to watch for

Manufacturer claims broad capability without dosage-form-specific DCGI approval for each · No consolidated documentation process across dosage forms · Facility segregation concerns raised for one dosage form but not addressed for others · Inconsistent quality standards claimed across different dosage forms

From the Compare section

Beta-lactam vs non-beta-lactam antibiotic manufacturing — what the facility rules mean for buyers

Penicillin-class antibiotics require fully dedicated manufacturing facilities. Cephalosporins require validated segregation. Non-beta-lactam antibiotics can share multi-product facilities. This affects which manufacturers can legitimately supply which antibiotic classes.

Complete COA
WHO-GMP certified facility

Sterility · Bacterial endotoxin · Particulate matter · Assay · pH — all required and documented per WHO-GMP batch release procedure.

  • All tests mandatory for batch release
ISO 9001 only facility

Sterility · Bacterial endotoxin · Particulate matter · Assay · pH — all required and documented per WHO-GMP batch release procedure.

  • Pharma-specific tests not mandated
Read Full Comparison

Certificate of Analysis

Request a sample COA with assay method and reference standard source specified

Which pharmacopoeial reference standard a lab uses reveals more about analytical rigor than the COA result itself.

#4 of 6

A Certificate of Analysis (COA) for an antibiotic must show the assay method used and the reference standard source. Ask which pharmacopoeial reference standards (IP/BP/USP) the manufacturer’s QC lab uses — a manufacturer unable to specify this is a warning sign about analytical rigor.

What a complete antibiotic COA must contain
Beyond standard parameters, antibiotic COAs should specify the assay method (typically HPLC) and confirm potency testing against a certified reference standard — critical since antibiotic potency, unlike simple identity, degrades measurably over shelf life and must be tracked precisely.

How to verify — step by step

  • Request a real sample COA: From an actual recent batch, not a template.

  • Ask which reference standard source is used: IP, BP, or USP certified reference standards specifically.

  • Confirm the assay method is specified: Typically HPLC for antibiotic potency testing.

  • For injectable antibiotics, confirm sterility is included: Mandatory, not optional, for this dosage form.

Parameter Why It Matters
Assay (potency) Confirms active ingredient at label strength — method-specific
Reference standard source Confirms testing is against a certified, traceable standard
Sterility (injectables only) Mandatory for injectable antibiotics
Dissolution (oral forms) Confirms release rate
Microbial limits Confirms contamination within acceptable range

Why this check matters for export
International regulators may specifically query the reference standard source used for antibiotic potency testing — a COA without this specified is treated as incomplete for dossier submission in some markets.

Red Flags to Watch For

Manufacturer cannot specify reference standard source · COA doesn’t state the assay method used · Sterility result missing from an injectable antibiotic COA · COA not available within 24 hours

Export References

Ask for export references in your specific target country — an existing COPP saves 6–12 months

If the antibiotic manufacturer has already registered products in your market, your registration timeline shrinks dramatically.

#5 of 6

A Certificate of Pharmaceutical Product (COPP) confirms a specific product is authorised for manufacture and sale in India. If an antibiotic manufacturer has already exported to your target country and holds an active COPP, your registration timeline can shorten by 6–12 months.

What is a COPP (Certificate of Pharmaceutical Product)?
A COPP is issued under the WHO Certification Scheme by CDSCO for products manufactured by a DCGI-licensed manufacturer at a WHO-GMP certified facility. Confirm the manufacturer’s COPP matches your exact antibiotic molecule, strength, and dosage form. (WHO Technical Report Series No. 986, Annex 10)

How to verify — step by step

  • Ask “Have you previously exported this antibiotic to [country]?” — request the specific product name and year of first registration.

  • Ask “Do you hold an active COPP for [country]?” — confirm it matches your exact molecule, strength, and dosage form.

  • Ask “Can you provide a CTD or ACTD dossier?” — export-experienced manufacturers typically hold ready dossiers.

  • Ask about a similar regulatory authority’s acceptance: NAFDAC or PPB experience often transfers well across African markets.

Why this check matters for export
Dossier review queues in Africa and the Middle East are long; an existing, molecule-and-form-matched COPP eliminates the initial 30–90 day waiting period entirely.

Red Flags To Watch For

Vague answers about prior export experience · COPP offered doesn’t match your specific molecule or dosage form · No CTD/ACTD dossier despite claimed export history · Cannot name a specific country or product previously registered

Documentation Speed

Test documentation turnaround time — 24 hours is the benchmark for antibiotic manufacturers too

The speed at which a manufacturer produces documentation reveals the depth of their regulatory readiness — before you sign any contract.

#6 of 6

Documentation turnaround time is a practical proxy for regulatory maturity. A well-organised, genuinely WHO-GMP compliant antibiotic manufacturer in India maintains all documentation in a structured, readily accessible system — WHO-GMP certificate, DCGI licence, COPP, sample COA, and stability data should all be retrievable within 24 hours.

The documentation turnaround test — run this before any purchase order
Send a formal documentation request specifying your exact antibiotic molecule, strength, and dosage form, and time the response. A commercially serious, production-ready manufacturer responds within 24 hours; anything beyond 48 hours signals the documents may not exist in a readily accessible form.

How to verify — step by step

  • Send a documentation request specifying your exact requirement: Molecule, strength, dosage form, and target country — ask for WHO-GMP certificate, DCGI approval, and sample COA.

  • Time the response: A benchmark manufacturer responds within 24 hours.

  • Request COPP and stability data next: These require more preparation but should arrive within 24-48 hours for existing export products.

  • Ask for ICH Zone IVb stability data specifically: Required by most tropical-climate importing countries — a manufacturer with export history should have this ready.

Why this check matters for export
Documentation delays typically indicate the product is not genuinely in regular commercial production, or the facility lacks a proper document management system — either scenario represents a supply chain risk for a serious buyer.

Red Flags To Watch For
No response within 48 hours to a documentation request · Documents arrive incomplete or as generic templates · Manufacturer asks for a purchase order before providing any documentation · Stability data unavailable despite claimed export experience

More Pharma Guide

Frequently asked questions

  • What WHO-GMP requirements apply specifically to antibiotic manufacturing?

    Penicillin-class antibiotics require completely dedicated, physically separated manufacturing facilities. Cephalosporins require validated segregation and air-handling controls in multi-product facilities. Non-beta-lactam antibiotics can be manufactured in validated multi-product facilities with appropriate cleaning validation.

    WHO Technical Report Series No. 986, Annex 2

  • Can one antibiotic manufacturer supply the same molecule in multiple dosage forms?

    Yes, if the manufacturer holds separate DCGI approvals for each dosage form. This allows a buyer to consolidate sourcing under one WHO-GMP certification and reduce the number of COPP applications required for their registration programme.

  • What should an antibiotic Certificate of Analysis contain?

    A complete COA shows batch number, dates, assay by a specified method (typically HPLC) against a certified reference standard, potency, dissolution (oral forms), sterility (injectables), and microbial limits — with actual numerical results, not just pass/fail.

    British Pharmacopoeia 2024

  • How long does it take to get a COPP for an antibiotic product from India?

    A fresh COPP application typically takes 30–90 days. Manufacturers with prior export experience to a specific country typically hold active COPPs providable within 24–48 hours.

    WHO Technical Report Series No. 986, Annex 10

  • Why do penicillin antibiotics need a dedicated manufacturing facility?

    Penicillin residues can cause severe allergic reactions, including anaphylaxis, in sensitive patients even at trace cross-contamination levels. WHO-GMP therefore mandates complete physical separation of penicillin manufacturing from all other pharmaceutical production to eliminate cross-contamination risk entirely.

    WHO Technical Report Series No. 986, Annex 2

9M India — passes all 6 checks

Ready to verify 9M India against your checklist?

WHO-GMP certificate, DCGI approval, sample COA, COPP, stability data — all available within 24 hours of your first enquiry.

Send an enquiry
View Antibiotic range
WhatsApp

WHO-GMP certified · DCGI approved · 15+ export countries · Birkoni, Chhattisgarh · Est. 2009

By Formulation Type
Tablets Capsules Granules & Powders Syrups Suspensions Solutions Ointments Creams Gels Injections Eye Drops Ear Drops External Liquid Dosage
By Therapeutic Segment
Antibiotics Pain Management Cardiovascular Diabetic Care CNS / Neurology Gastrointestinal Respiratory Dermatology Vitamins & Minerals Ophthalmic Paediatrics Anti Infective

Looking for something specific?

At 9M India Limited, trust through quality, transparency, performance.

Get In Touch With Us

Contract Manufacturing

Contract Manufacturing

3rd Party Manufacturing

3rd Party Manufacturing

Institutional Tenders

Institutional Tenders

Generic Medicines

Generic Medicines

OTC Products

OTC Products

Regulatory Services

QC & QA